Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

• DOI: 10.4251/wjgo.v16.i6.2504
• Publication Date: 2024-06-14T07:43:34Z
• Authors: Di Pan; Hao-Nan Liu; Zhi-Yuan Yao; Xiao-Xiao Chen; Yu-Qi Li; Jing-Jing Zhu; Zheng-Xiang Han; Xiao-Bing Qin
• Keywords: Baseline (sea); Hepatitis virus; Viral Hepatitis

BACKGROUND Although the combination of lenvatinib and PD-1 inhibitors has become standard regimen for treatment advanced hepatocellular carcinoma (HCC), real data on impact baseline hepatitis B virus (HBV)-DNA levels clinical efficacy this is still limited. AIM To evaluate effectiveness camrelizumab combined with in patients HCC at varying HBV-DNA. METHODS One hundred twenty who received were categorized into two cohorts: HBV-DNA ≤ 2000 (n = 66) > 54). The main outcomes measured overall survival (OS) progression-free (PFS), while additional included rate objective response (ORR), disease control (DCR), any negative events. Cox proportional hazards regression analysis revealed independent predictors OS, leading to creation a nomogram incorporating these variables. RESULTS median PFS was 8.32 months group, which similar 7.80 observed HBV DNA group (P 0.88). Likewise, there no notable variation OS between groups, durations 13.30 14.20 respectively 0.14). ORR DCR compared showing 19.70% vs 33.33% 0.09) 72.73% 74.07% 0.87). emphasized importance antiviral as predictor patient results, portal vein tumor thrombus Barcelona Clinic Liver Cancer staging following closely behind. CONCLUSION HBV-associated treated are not significantly affected by viral load.